Celldex Therapeutics, Inc. (CLDX)

3.79
NASDAQ
Prev Close 3.79
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.75 / 12.58
Exchange NASDAQ
Shares Outstanding 12.44B
Market Cap 47.15M
Div & Yield N.A. (N.A)
Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock

Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Weak On High Volume

Celldex Therapeutics (CLDX) Weak On High Volume

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Short Interest In Celldex Therapeutics Increases 12%

Short Interest In Celldex Therapeutics Increases 12%

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 2,772,151 share increase in total short interest for Celldex Therapeutics, Inc. , to 25,763,736, an increase of 12.06% since 03/15/2016.

Anavex Plays the Orphan Drug Stock Promotion Game

Anavex Plays the Orphan Drug Stock Promotion Game

Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

7 Stocks Under $10 to Trade for Breakout Gains

7 Stocks Under $10 to Trade for Breakout Gains

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock

Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

6 Biotech Stocks Under $10 to Trade for Big Breakouts

6 Biotech Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)

Today's Dead Cat Bounce Stock Is Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Celldex Therapeutics (CLDX) Stock Downgraded at Jefferies

Celldex Therapeutics (CLDX) Stock Downgraded at Jefferies

Jefferies downgraded Celldex Therapeutics (CLDX) stock and cut its price target to $4 from $31.

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.

Here's Why Celldex (CLDX) Stock is Plunging Today

Here's Why Celldex (CLDX) Stock is Plunging Today

Celldex (CLDX) stock is plummeting in early-morning trading on Monday after an independent board recommended the company discontinue its Phase 3 trial for a treatment for glioblastoma.

Heavy Trading On Celldex Therapeutics (CLDX) Before Market Open

Heavy Trading On Celldex Therapeutics (CLDX) Before Market Open

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a pre-market mover with heavy volume candidate

Celldex Brain Tumor Vaccine Fails Pivotal Clinical Trial

Celldex Brain Tumor Vaccine Fails Pivotal Clinical Trial

There's bad news from Celldex Therapeutics on Monday. The pivotal brain tumor clinical trial involving the company's experimental cancer vaccine Rintega was halted for futility.

Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock

Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Celldex Therapeutics (CLDX) Showing Signs Of Perilous Reversal Today

Celldex Therapeutics (CLDX) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Stock Price Target Lowered at Cantor Fitzgerald

Celldex Therapeutics (CLDX) Stock Price Target Lowered at Cantor Fitzgerald

Cantor Fitzgerald reduced its price target on Celldex Therapeutics (CLDX) stock and maintained its ‘buy’ rating on Friday morning.

Celldex Therapeutics (CLDX) Stock Gaining on Q4 Results

Celldex Therapeutics (CLDX) Stock Gaining on Q4 Results

Celldex Therapeutics (CLDX) stock is advancing on Thursday after the company reported a narrower loss than expected in the 2015 fourth quarter before today’s market open.

TheStreet Quant Rating: D- (Sell)